Search
Tafasitamab
go.drugbank.com/drugs/DB15044ApprovedInvestigational[L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling. … leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL))[L15302] has made it a desirable target in the treatment these B-cell malignancies.
Remibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigational[L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators. … Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria.
Pyrantel
go.drugbank.com/drugs/DB11156ApprovedVet approvedPyrantel is on the World Health Organization's List of Essential Medicines, which are the safest and most effective medicines required in a functioning health system [L1901], [L1902]. … Pyrantel is mainly available in formulations for dogs and cats as the embonate salt, containing a 34.7% pyrantel base [L1900].
Products: PIREL® SUSPENSION AL 5%Clomifene
go.drugbank.com/drugs/DB00882ApprovedInvestigationalA triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.
Synonyms: 2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamineMometasone furoate
go.drugbank.com/drugs/DB14512ApprovedInvestigationalVet approvedMometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its different indications[FDA Label][F4292,F4295]. … Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[FDA Label][F4292,F4295].
Mixtures: M-FURO FA %0.1 + %2 KREM, 30 GProducts: MOMETASONFUROAT 1A PH 50UG, MOMETASONFUROAT AL 50UG/SPTolrestat
go.drugbank.com/drugs/DB02383ApprovedWithdrawnWhile it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. … Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications.
Categories: Drugs Used in DiabetesPhloxine B
go.drugbank.com/drugs/DB13911ApprovedWithdrawnPhloxine B (commonly known simply as phloxine, also known as D&C RED NO. 28) is a color additive which is used both as an inactive ingredient to provide color to products, or as a colorant in dental disclosing
Categories: Compounds used in a research, industrial, or household settingConcizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … [A264883,A264878] In patients with hemophilia A or B - characterized by deficiencies in clotting factors VIII or IX, respectively - the traditional treatment involves replacement of the missing clotting
Perampanel
go.drugbank.com/drugs/DB08883ApprovedInvestigationalPerampanel is a noncompetitive AMPA glutamate receptor antagonist. … The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.
Pegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigationalPegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease.